Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study

Advances in Therapy

Volumn 30, Issue 6, 2013, Pages 630-643

  Bogner, Johannes R ^a   Kutaiman, Ammar ^b   Esguerra Alcalen, Melanie ^c   Heldner, Stephanie ^d   Arvis, Pierre ^e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Al Noor Hospital   (United Arab Emirates)

^c San Juan de Dios Hospital   (Philippines)

^d BAYER PHARMA AG   (Germany)

^e Bayer Santé ^*  (France)

Author keywords

Broad spectrum antibiotic; Complicated skin and skin structure infections; Fluoroquinolones; Moxifloxacin; Observational study

Indexed keywords

MOXIFLOXACIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; COMORBIDITY; COMPLICATED SKIN AND SKIN STRUCTURE INFECTION; CONTROLLED STUDY; DEHYDRATION; DIABETES MELLITUS; DIABETIC FOOT; DIARRHEA; DIZZINESS; DRUG DOSE SEQUENCE; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; NAUSEA; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PRURITUS; RASH; SKIN ABSCESS; SKIN INFECTION; SKIN STRUCTURE; SYMPTOMATOLOGY; WOUND INFECTION;

ABSCESS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BITES AND STINGS; CELLULITIS; COHORT STUDIES; DEBRIDEMENT; DIABETIC FOOT; DRAINAGE; ERYSIPELAS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES; SKIN DISEASES, BACTERIAL; SKIN ULCER; SURGICAL WOUND INFECTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880323530     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0038-z     Document Type: Article

References (28)

1. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65:iii35-44.
2. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592-8.
3. Leaper DJ, van Goor H, Reilly J, et al. Surgical site infection - a European perspective of incidence and economic burden. Int Wound J. 2004;1:247-73.
4. Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin and soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical and economic outcomes. Infect Con Hosp Epidemiol. 2007;28:1290-8.
5. Cainzos M. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections - are they applicable today? Clin Microbiol Infect. 2008;14:9-18.
6. Napolitano LM. Severe soft tissue infections. Infect Dis Clin N Am. 2009;23:571-91.
7. Moet GJ, Jones RN, Biedenbacj DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diag Microbiol Infect Dis. 2007;57:7-13.
8. Brook I. Microbiology of polymicrobial abscesses and implications for therapy. J Antimicrob Chemother. 2002;50:805-10.
9. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52:i3-17.
10. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-406.
11. May AK, Stafford RE, Bulger EM, et al. Surgical Infection Society Guidelines. Treatment of complicated skin and soft tissue infections. Surg Infect. 2009;10:467-99.
12. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-55.
13. Lipsky BA, Peters EJ, Berendt AR, et al. Specific guidelines for the treatment of diabetic foot infections 2011. Diabetes Metab Res Rev. 2012;28:234-5.
14. Giordano P, Weber K, Gesin G, Kubert J. Skin and skin structure infections: treatment with newer generation fluoroquinolones. Ther Clin Risk Manag. 2007;3:309-17.
15. Guay D. Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag. 2006;2:4117-34.
16. Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, STIC Study Group, et al. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection. 2009;37:407-17.
17. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents. 2005;26:357-65.
18. Gyssens IC, Dryden M, Kujath P, et al. A randomised trial of the efficacy and safety of sequential IV/oral moxifloxacin monotherapy versus IV piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother. 2011;66:2632-42.
19. European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Available at: www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/ WC500003417.pdf. Last accessed 30 May 2013.
20. Avelox (moxifloxacin 400 mg/250 ml solution for infusion) (product information). Leverkusen, Germany: Bayer Pharma AG; 2011.
21. Jepsen P, Johnsen SP, Gillman MW, Sørensen HT. Interpretation of observational studies. Heart. 2004;90:956-60.
22. Suvarna V. Phase IV of drug development. Perspect Clin Res. 2010;1:57-60.
23. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. Available at: www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM071185.pdf. Last accessed 30 May 2013.
24. Schaper NC, Dryden M, Kujath P, et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/ clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection. 2013;41:175-86.
25. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010;51:895-903.
26. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an analysis of 14 years of clinical data. Drugs R D. 2012;12:71-100.
27. Moran GJ, Abrahamian FM, Lovecchio F, Talan DA. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J Emerg Med. 2013;44:e397-412.
28. Concia E. Therapy of SSTI and role of tigecycline. Infez Med. 2009;17:64-76.